- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001481
The Role of Hormones in Postpartum Mood Disorders
An Endocrine Model for Postpartum Mood Disorders
Determine whether postpartum depression is triggered by the abrupt withdrawal of estrogen and progesterone.
The appearance of mood and behavioral symptoms during pregnancy and the postpartum period has been extensively reported. While there has been much speculation about possible biologically based etiologies for postpartum disorders (PPD), none has ever been confirmed. Preliminary results from two related studies (protocols 90-M-0088, 92-M-0174) provide evidence that women with menstrual cycle related mood disorder, but not controls, experience mood disturbances during exogenous replacement of physiologic levels of gonadal steroids. The present protocol is designed to create a "scaled-down" hormonal milieu of pregnancy and the puerperium in order to determine whether women who have had a previous episode of postpartum major effective episode will experience differential mood and behavioral effects compared with controls and to determine whether it is the abrupt withdrawal of gonadal steroids or the prolonged exposure to gonadal steroids that is associated with mood symptoms. Supraphysiologic plasma levels of gonadal steroids will be established, maintained, and then rapidly reduced, simulating the hormonal events that occur during pregnancy and parturition. This will be accomplished by administering estradiol and progesterone to women who are pretreated with a gonadotropin releasing hormone (GnRH) agonist (Lupron). After eight weeks, administration of gonadal steroids will be stopped in one group of patients and controls, and a sudden decline in the plasma hormone levels will be precipitated. Another group will be maintained on supraphysiologic levels of estrogen and progesterone for an additional month. Outcome measures will include mood, behavioral and hormonal parameters (a separate protocol done in collaboration with NICHD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Peter J Schmidt, M.D.
- Phone Number: (301) 496-6120
- Email: peterschmidt@mail.nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
A. Group 1: Women with a history of postpartum depression:
- A history of DSM-IV major depression or hypomanic/manic episode that occurred within three months of childbirth (as determined by a SCID interview);
- has been well for a minimum of one year;
- a regular menstrual cycle for at least three months;
- age 18-50;
- not pregnant, not lactating and in good medical health;
- medication free (including birth control pills);
- no history of puerperal suicide attempts or psychotic episodes requiring hospitalization.
B. Group 2: Women with a history of Major Depressive Disorder
- A history of DSM-IV major depression episode(s) occurring outside of pregnancy and not within three months postpartum;
- has been well for a minimum of one year;
- a regular menstrual cycle for at least three months;
- age 18-50;
- not pregnant, not lactating and in good medical health;
- medication free (including birth control pills);
- no history of suicide attempts or psychotic episodes requiring hospitalization.
C. Group 3: Normal Controls
Controls will meet all criteria specified except they must not have any past or present Axis I diagnosis or evidence of menstrually related mood disorders.
EXCLUSION CRITERIA:
Patients will not be permitted to enter this protocol if they have important clinical or laboratory abnormalities including any history of the following:
endometriosis;
undiagnosed enlargement of the ovaries;
liver disease;
breast cancer;
a history of blood clots in the legs or lungs;
undiagnosed vaginal bleeding;
porphyria;
diabetes mellitus;
malignant melanoma;
gallbladder or pancreatic disease;
heart or kidney disease;
cerebrovascular disease (stroke);
cigarette smoking;
a history of suicide attempts or psychotic episodes requiring hospitalization;
recurrent migraine headaches;
pregnancy (patients will be warned not to become pregnant during the study and will be advised to employ barrier contraceptive methods;
pregnancy-related medical conditions such as hyperemesis gravidarum, pretoxemia and toxemia, deep vein thrombosis (DVT) and bleeding diathesis;
Any woman with a first degree relative (immediate family) with premenopausal breast cancer or breast cancer presenting in both breasts or any woman who has multiple family members (greater than three relatives) with postmenopausal breast cancer will also be excluded from participating in this protocol;
Any woman meeting the Stages of Reproductive Aging Workshop Criteria (STRAW) for the perimenopause will be excluded from participation. Specifically, we will exclude any woman with an elevated plasma FSH level (greater than or equal to 14 IU/L) and with menstrual cycle variability of > 7 days different from their normal cycle length;
Subjects who are unable to provide informed consent;
NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group 1, Hormone and Placebo Group
8 weeks of hormonal addback plus 4 weeks of placebo
|
To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
|
Active Comparator: Group 2, Continued Replacement Group
12 weeks of hormone addback
|
To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcome measures will include mood, behavioral, and hormonal parameters as well as response to o-CRH.
Time Frame: ongoing
|
Outcome measures will include mood, behavioral, and hormonal parameters as well as response to o-CRH.
|
ongoing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Peter J Schmidt, M.D., National Institute of Mental Health (NIMH)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pregnancy Complications
- Puerperal Disorders
- Depressive Disorder
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Depression
- Depression, Postpartum
- Mood Disorders
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Progestins
- Estradiol
- Progesterone
Other Study ID Numbers
- 950097
- 95-M-0097
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Depression
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
-
British Columbia Children's HospitalActive, not recruiting
-
University of RochesterMae Stone Goode FoundationCompletedPostpartum Depression | Postpartum AnxietyUnited States
-
Hacettepe UniversityCompletedQuality of Life | Postpartum Depression | Nursing Caries | Nurse's Role | Postpartum Disorder | Postpartum AnxietyTurkey
Clinical Trials on Estradiol
-
Medical College of WisconsinTerminatedTransgenderism | Clotting DisorderUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedOral Contraceptive | HemostasisGermany, Israel, Italy, Spain
-
Wake Forest University Health SciencesRecruitingRecurrent Urinary Tract InfectionUnited States
-
Oregon Health and Science UniversityCompleted
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal Atrophy
-
University of HelsinkiPäivikki and Sakari Sohlberg Foundation, Finland; Finnish Medical Foundation; Emil Aaltonen FoundationCompletedCardiovascular Disease | Postmenopausal Vasomotor SymptomsFinland
-
Mayo ClinicCompletedCardiovascular Risk ReductionUnited States
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyGermany
-
Mahidol UniversityCompletedOvulation InhibitionThailand
-
Children's Hospital Medical Center, CincinnatiPatty Brisben Foundation For Women's Sexual HealthCompletedPrimary Ovarian InsufficiencyUnited States